-- 
Clal Biotechnology Gains to Highest in Month on Lymphoma Study

-- B y   S h o s h a n n a   S o l o m o n
-- 
2011-09-08T08:56:48Z

-- http://www.bloomberg.com/news/2011-09-08/clal-biotechnology-gains-to-highest-in-month-on-lymphoma-study.html
Clal Biotechnology Industries Ltd. (CBI) 
rose to the highest level since Aug. 4 after the company said a
Phase II study of its Curetech Ltd. unitâ€™s CT-011 lymphoma drug
proved effective when taken by patients.  The shares gained 2.9 percent to 15.70 shekels at 11:13
a.m. on the Tel Aviv Stock Exchange, giving Clal Biotechnology,
which invests in companies in the biological sector, a market
value of 1.6 billion shekels ($434 million).  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  